Department of Dermatology, XiangYa Hospital, Central South University, Changsha, Hunan 410008, China.
Cancer Lett. 2013 Sep 1;337(2):285-92. doi: 10.1016/j.canlet.2013.04.025. Epub 2013 Apr 25.
CD147 and ABCG2 both have been reported to mediate Multidrug resistance (MDR) in breast cancer. Recent study demonstrates that CD147 could form a complex with ABCG2 on the cell membrane in primary effusion lymphoma. However, whether these two molecules regulate each other in breast cancer and result in MDR is not clear. We established four MCF-7 cell lines transfected with CD147 and/or ABCG2 and found that CD147 could increase the expression and dimerization of ABCG2, affect its cellular localization and regulate its drug transporter function. The findings derived from cells were confirmed subsequently in clinic samples of chemotherapy-sensitive/resistant breast cancer.
CD147 和 ABCG2 均被报道可介导乳腺癌的多药耐药（MDR）。最近的研究表明，CD147 可在原发性渗出性淋巴瘤的细胞膜上与 ABCG2 形成复合物。然而，这两个分子是否在乳腺癌中相互调节并导致 MDR 尚不清楚。我们建立了四个转染 CD147 和/或 ABCG2 的 MCF-7 细胞系，发现 CD147 可以增加 ABCG2 的表达和二聚化，影响其细胞定位，并调节其药物转运功能。随后在化疗敏感/耐药乳腺癌的临床样本中证实了这些细胞中的发现。
